Baird analyst Joel Beatty raised the firm’s price target on Amylyx (AMLX) to $19 from $10 and keeps an Outperform rating on the shares. The firm updated its model given increased confidence in Avextide’s penetration rate in PBH.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $16 from $14 at BofA
- Strategic Growth and Financial Flexibility Position Amylyx Pharmaceuticals for Success: Buy Rating with $16 Price Target
- Amylyx price target raised to $25 from $17 at Guggenheim
- Amylyx Pharmaceuticals Announces $164 Million Stock Offering
- Amylyx 17.5M share Spot Secondary priced at $10.00